Trivalent CAR-T cells co-targeting HER2, IL-13Rα2, and EphA2 could overcome interpatient variability, achieve a capture of antigens in nearly 100% of tumor cells, avoid antigen escape, and were shown to increase the survival in an orthotopic xenograft model of GBM. This evidence concerns the gene EPHA2 and glioblastoma.